Phase I Clinical Trial of Serotherapy in Patients with Acute Myeloid Leukemia with an Immunoglobulin M Monoclonal Antibody to CD15

Edward D. Ball, Kathy Selvaggi, Laura Clark, Vicki Malley, Jeannette Persichetti, Margarida Demagelhaus Silverman, David Hurd, Roger Herzig

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Sixteen patients with acute myeloid leukemia (AML) were treated with a continuous i.v. infusion of mAb PM-81, an IgM mAb directed against the cellular differentiation antigen CD15, which is expressed on leukemia cells of >95% of patients with AML. MAb PM-81, also referred to as MDX-11, is capable of activating human and rabbit complement and lysing CD15-positive AML cells. In this Phase I study, patients were treated with 0.5, 1.0, or 1.5 mg/kg MDX-11 delivered over a 24-h period followed by conventional chemotherapy. Transient decreases in circulating blast cells postinfusion (prior to chemotherapy) were observed at all doses. We were able to show MDX-11 binding to bone marrow blasts in those patients who achieved stable serum levels of MDX-11. Serum MDX-11 was detectable at the 1.0- and 1.5-mg/kg doses. Doses of 0.5 and 1.0 mg/kg were generally well tolerated, with no toxicities greater than grade II (Eastern Cooperative Oncology Group) reported. However, two of five patients receiving the 1.5-mg/kg dose experienced grade IV toxicities that resolved with treatment (one of these patients completed the infusion). Common toxicities reported included fever, chills, and hypotension. Only one patient developed human antimouse antibodies at 4 weeks posttreatment. This study determined that 1.0 mg/kg is a biologically effective dose that can be administered safely with little toxicity. Based on these results, we are pursuing a Phase I/II study of MDX-11 infusion following chemotherapy for patients with relapsed AML.

Original languageEnglish (US)
Pages (from-to)965-972
Number of pages8
JournalClinical Cancer Research
Volume1
Issue number9
StatePublished - Sep 1 1995

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase I Clinical Trial of Serotherapy in Patients with Acute Myeloid Leukemia with an Immunoglobulin M Monoclonal Antibody to CD15'. Together they form a unique fingerprint.

  • Cite this

    Ball, E. D., Selvaggi, K., Clark, L., Malley, V., Persichetti, J., Silverman, M. D., Hurd, D., & Herzig, R. (1995). Phase I Clinical Trial of Serotherapy in Patients with Acute Myeloid Leukemia with an Immunoglobulin M Monoclonal Antibody to CD15. Clinical Cancer Research, 1(9), 965-972.